Copiktra® (duvelisib) – Drug safety communication
June 30, 2022 - The FDA announced a warning that results from a clinical trial show a possible increased risk of death with Secura Bio’s Copiktra (duvelisib) compared to Arzerra® (ofatumumab) for treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Top